osimertinib
astrazeneca
['flaura']
 i do agree on mrd, not sure we could work out the benefit of 1st gen tki by using the hr of flaura but we could hopefully agree that not exposing pts at progression to osi was a substandard treatment.
Medical Oncologist, department of oncology at the University hospital of Geneva (HUG). All opinions expressed here are my own